PROJECT

Projects

Summary of Investment Information

Project Number

49198

Company Name

Anhui Huaheng Biotechnology Co.,Ltd

Date SPI Disclosed

Nov 20, 2024

Country

China

Region

East Asia and the Pacific

Projected Board Date

Dec 20, 2024

Environmental Category

B - Limited

Status

Pending Approval

Last Updated Date

Nov 20, 2024

Department

Regional Industry - MAS Asia & Pac

Industry

Agribusiness and Forestry

Sector

Other Food

Project Description

Anhui Huaheng Biotechnology Co., Ltd. (AHB or the Company) is a leading manufacturer of amino acids and other bio-based products in the People’s Republic of China (PRC). IFC is proposing to provide up to RMB 500 million (equivalent to US$70.5 million) in the form of a Green Loan (the Loan) to Qinhuangdao Huaheng Bioengineering Co., Ltd. (QHB), a wholly-owned subsidiary of AHB. The IFC proceeds will be used to fund the capex and working capital needs of malic acid and L-Tryptophan production (the Project).

Associated Advisory Engagement

IFC will provide support to AHB on its near-term expansion outside of China, to bring the technology and affordable nutrition manufacturing capability to wider emerging markets. Under current Upstream and Advisory program to systematically address South-South activities in Asia, IFC will invite AHB to thematic seminars and workshops that share knowledge and experiences of Chinese manufacturers conducting outbound investments, as the Company moves forward with implementation.

Sponsor / Cost / Location

Development Impact

E&S Category Rationale / Risks and Mitigation